Business
NeoGenomics Announces Plans to Expand Global Footprint in Pharma Services by Opening Clinical Research Laboratory in Suzhou, China
NeoGenomics continues to build its world-class pharma clinical research capabilities to include servicing Greater China-based clinical trialsFORT MYERS, FL /
About this update from Neogenomics, Inc.
[{"type":"text","content":"NeoGenomics continues to build its world-class pharma clinical research capabilities to include servicing Greater China-based clinical trialsFORT MYERS, FL / ACCESSWIRE / October 13, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced plans to open a state-of-the-art research laboratory in China in association with the new lab PPD, Inc. (NASDAQ: PPD) is opening in Suzhou. Within PPD's 67,000-square-foot (6,224-square-meter) facility, NeoGenomics will maintain a dedicated laboratory and additional shared lab operational space. The NeoGenomics laboratory is expected to support Greater China-focused clinical trials and testing for global and local Chinese pharmaceutical companies. Based in Suzhou New District, Jiangsu Province, the NeoGenomics research facility will be operational in 2021. NeoGenomics will offer pharma research services, including early translational and clinical research trial studies supporting global pharmaceutical initiatives.\"We have kept our pharma customers' needs as top priority by strategically expanding our footprint in Europe, Asia-Pacific and now, into Greater China,\" said Douglas VanOort, NeoGenomics' Chairman and Chief Executive Officer. \"Last year we expanded our global presence by inaugurating our Singapore clinical lab in Science Park. This year, despite the COVID-19 pandemic, we have proceeded with our expansion plans in China to continue to provide the best-in-class service in oncology.\"In a very similar arrangement to the laboratory opened in Singapore in 2019, NeoGenomics will establish services in the same building as PPD. This continues the multi-year alliance between the two companies and highlights the complementarity of technologies and service offerings of both organizations.\"With the new Fort Myers laboratory expansion in progress, our labs in Houston, Aliso Viejo, and San Diego (La Jolla) within North America, and in Rolle, Switzerland and Singapore, we are truly transforming our pharma services business into a world-class suite for global pharma clinical research and companion diagnostic needs,\" added VanOort. \"The Suzhou lab gives us a substantial technology and regional advantage to serve our pharma clients quickly and efficiently.\"About NeoGenomics, Inc.NeoGenomics, Inc. specializes in cancer genetics...